ANGPTL1 overexpression inhibits the MET receptor-AKT/ERK-Egr-1-Slug signaling cascade, repressing the epithelial–mesenchymal transition and thereby counteracting sorafenib resistance and cancer stemness in HCC cells (53). This evidence concerns the gene ANGPTL1 and hepatocellular carcinoma.